• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

使用塔非酰胺治疗的心脏淀粉样变性的首次随访，通过骨闪烁显像的绝对定量评估

First Follow-Up of Cardiac Amyloidosis Treated by Tafamidis, Evaluated by Absolute Quantification in Bone Scintigraphy.

作者信息

Bellevre Dimitri, Bailliez Alban, Maréchaux Sylvestre, Manrique Alain, Mouquet Frédéric

机构信息

Department of Cardiology, Normandy University, Caen, France.

Department of Nuclear Medicine, Lille Catholic Institute Hospital Group, Lomme, France.

出版信息

JACC Case Rep. 2021 Jan 20;3(1):133-135. doi: 10.1016/j.jaccas.2020.11.036. eCollection 2021 Jan.

DOI:10.1016/j.jaccas.2020.11.036
PMID:34317486
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC8305621/
Abstract

Assessment of absolute myocardial hydroxydimethylene diphosphonate-technetium-99m uptake using standardized uptake value with a single-photon emission computed tomography-computed tomography cadmium zinc telluride camera (Discovery NM/CT 670CZT, GE Healthcare, Chicago, Illinois) in a patient with cardiac transthyretin-related amyloidosis treated with tafamidis showed a decrease in hydroxydimethylene diphosphonate cardiac uptake. This imaging technique should be helpful in monitoring therapy and evaluating prognosis. ().

摘要

在一名接受塔非米地治疗的心脏转甲状腺素蛋白相关淀粉样变性患者中，使用标准化摄取值，通过单光子发射计算机断层扫描-计算机断层扫描碲化镉锌相机（Discovery NM/CT 670CZT，GE医疗集团，伊利诺伊州芝加哥）评估心肌羟基二亚甲基二膦酸盐-锝-99m的绝对摄取量，结果显示心肌羟基二亚甲基二膦酸盐摄取量降低。这种成像技术应有助于监测治疗和评估预后。（）

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d62d/8305621/81af7a1fecc9/gr1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d62d/8305621/4a85b83cd781/fx1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d62d/8305621/81af7a1fecc9/gr1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d62d/8305621/4a85b83cd781/fx1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d62d/8305621/81af7a1fecc9/gr1.jpg

相似文献

1
First Follow-Up of Cardiac Amyloidosis Treated by Tafamidis, Evaluated by Absolute Quantification in Bone Scintigraphy.使用塔非酰胺治疗的心脏淀粉样变性的首次随访，通过骨闪烁显像的绝对定量评估
JACC Case Rep. 2021 Jan 20;3(1):133-135. doi: 10.1016/j.jaccas.2020.11.036. eCollection 2021 Jan.
2
Quantitation of myocardial Tc-HMDP uptake with new SPECT/CT cadmium zinc telluride (CZT) camera in patients with transthyretin-related cardiac amyloidosis: Ready for clinical use?新型 SPECT/CT 碲锌镉（CZT）相机检测转甲状腺素蛋白相关心脏淀粉样变患者心肌 Tc-HMDP 摄取：是否准备好临床应用？
J Nucl Cardiol. 2022 Apr;29(2):506-514. doi: 10.1007/s12350-020-02274-2. Epub 2020 Jul 26.
3
Monitoring tafamidis treatment with quantitative SPECT/CT in transthyretin amyloid cardiomyopathy.用定量 SPECT/CT 监测转甲状腺素蛋白淀粉样心肌病中的塔法米迪治疗。
Eur Heart J Cardiovasc Imaging. 2023 Jul 24;24(8):1019-1030. doi: 10.1093/ehjci/jead030.
4
A case of cardiac amyloidosis incidentally detected by bone scintigraphy.一例通过骨闪烁显像意外发现的心脏淀粉样变性病例。
Asia Ocean J Nucl Med Biol. 2021 Winter;9(1):71-75. doi: 10.22038/AOJNMB.2020.50508.1350.
5
Extracardiac Accumulation of Technetium-99m-Pyrophosphate in Transthyretin Cardiac Amyloidosis.转甲状腺素蛋白心脏淀粉样变中99m锝-焦磷酸盐的心外积聚
JACC Case Rep. 2021 May 12;3(7):1069-1074. doi: 10.1016/j.jaccas.2021.02.015. eCollection 2021 Jul 7.
6
Prognostic Value of Tc-HMDP Scintigraphy in Elderly Patients With Chronic Heart Failure.Tc-HMDP 闪烁显像对老年慢性心力衰竭患者的预后价值。
Heart Lung Circ. 2022 May;31(5):629-637. doi: 10.1016/j.hlc.2021.11.018. Epub 2022 Jan 19.
7
Biopsy Evidence of Sequential Transthyretin and Immunoglobulin Light-Chain Cardiac Amyloidosis in the Same Patient.同一患者中甲状腺素运载蛋白和免疫球蛋白轻链型心脏淀粉样变的序贯活检证据
JACC Case Rep. 2021 Mar 17;3(3):450-454. doi: 10.1016/j.jaccas.2020.12.047. eCollection 2021 Mar.
8
Single-photon emission computed tomography/computed tomography quantification of Tc-99m pyrophosphate uptake to assess tafamidis treatment response in transthyretin cardiac amyloidosis.利用单光子发射计算机断层扫描/计算机断层扫描对99m锝焦磷酸盐摄取进行定量分析，以评估他氟米他在转甲状腺素蛋白心脏淀粉样变中的治疗反应。
J Nucl Cardiol. 2024 Dec;42:102056. doi: 10.1016/j.nuclcard.2024.102056. Epub 2024 Oct 9.
9
Bone scintigraphy with (99m)technetium-hydroxymethylene diphosphonate allows early diagnosis of cardiac involvement in patients with transthyretin-derived systemic amyloidosis.锝[99mTc]羟甲基二膦酸盐骨闪烁扫描术可早期诊断转甲状腺素蛋白衍生的系统性淀粉样变患者的心脏受累。
Amyloid. 2014 Mar;21(1):35-44. doi: 10.3109/13506129.2013.871250. Epub 2014 Jan 23.
10
Usefulness of (99m)Tc-HMDP scintigraphy for the etiologic diagnosis and prognosis of cardiac amyloidosis.(99m)Tc-HMDP 闪烁显像用于心脏淀粉样变性的病因诊断和预后判断的价值。
Amyloid. 2015;22(4):210-20. doi: 10.3109/13506129.2015.1072089. Epub 2015 Oct 14.

引用本文的文献

1
Transthyretin Amyloid Cardiomyopathy: Current Diagnostic Approach and Risk Stratification with Multimodality Imaging.转甲状腺素蛋白淀粉样心肌病：多模态成像的当前诊断方法和风险分层
J Clin Med. 2025 Mar 16;14(6):2014. doi: 10.3390/jcm14062014.
2
Impact of Tafamidis on [Tc]Tc-pyrophosphate Scintigraphy in Ala97Ser Hereditary Transthyretin amyloid cardiomyopathy: significant initial reduction with stable Long-Term effects.他法米地对Ala97Ser遗传性转甲状腺素蛋白淀粉样心肌病患者[锝]锝-焦磷酸盐闪烁扫描的影响：初期显著降低，长期效果稳定
Eur J Nucl Med Mol Imaging. 2025 Apr;52(5):1853-1863. doi: 10.1007/s00259-025-07079-4. Epub 2025 Jan 13.
3

本文引用的文献

1
Tafamidis Treatment for Patients with Transthyretin Amyloid Cardiomyopathy.特发性甲状腺素运载蛋白淀粉样变心肌病患者的塔法米迪治疗。
N Engl J Med. 2018 Sep 13;379(11):1007-1016. doi: 10.1056/NEJMoa1805689. Epub 2018 Aug 27.
2
Nonbiopsy Diagnosis of Cardiac Transthyretin Amyloidosis.非活检诊断心脏转甲状腺素淀粉样变性。
Circulation. 2016 Jun 14;133(24):2404-12. doi: 10.1161/CIRCULATIONAHA.116.021612. Epub 2016 Apr 22.
Tafamidis improves myocardial longitudinal strain in A97S transthyretin cardiac amyloidosis.
他法米地斯可改善A97S转甲状腺素蛋白心脏淀粉样变性患者的心肌纵向应变。
Ther Adv Chronic Dis. 2024 Jan 11;15:20406223231222828. doi: 10.1177/20406223231222828. eCollection 2024.
4
Use of Technetium-99m-Pyrophosphate Single-Photon Emission Computed Tomography/Computed Tomography in Monitoring Therapeutic Changes of Eplontersen in Patients With Hereditary Transthyretin Amyloid Cardiomyopathy.应用锝-99m-焦磷酸盐单光子发射计算机断层扫描/计算机断层扫描监测遗传性转甲状腺素蛋白淀粉样心肌病患者依罗替尼治疗的变化。
J Am Heart Assoc. 2024 Jan 16;13(2):e030512. doi: 10.1161/JAHA.123.030512. Epub 2024 Jan 12.
5
Cardiac [Tc]Tc-hydroxydiphosphonate uptake on bone scintigraphy in patients with hereditary transthyretin amyloidosis: an early follow-up marker?遗传性转甲状腺素蛋白淀粉样变性患者骨骼闪烁显像时心脏 [Tc]Tc-羟膦酸盐摄取：早期随访标志物？
Eur J Nucl Med Mol Imaging. 2024 Feb;51(3):681-690. doi: 10.1007/s00259-023-06459-y. Epub 2023 Oct 16.
6
Quantitative SPECT/CT Parameters in the Assessment of Transthyretin Cardiac Amyloidosis-A New Dimension of Molecular Imaging.定量SPECT/CT参数在转甲状腺素蛋白心脏淀粉样变评估中的应用——分子成像的新维度
J Cardiovasc Dev Dis. 2023 May 31;10(6):242. doi: 10.3390/jcdd10060242.
7
Follow-up Tc-99 m pyrophosphate cardiac scan for patients with transthyretin cardiac amyloidosis treated with tafamidis.用特立氟胺治疗转甲状腺素蛋白心脏淀粉样变患者后的 Tc-99m 焦磷酸盐心脏扫描随访。
Jpn J Radiol. 2023 Aug;41(8):882-888. doi: 10.1007/s11604-023-01403-4. Epub 2023 Mar 15.
8
Monitoring tafamidis treatment with quantitative SPECT/CT in transthyretin amyloid cardiomyopathy.用定量 SPECT/CT 监测转甲状腺素蛋白淀粉样心肌病中的塔法米迪治疗。
Eur Heart J Cardiovasc Imaging. 2023 Jul 24;24(8):1019-1030. doi: 10.1093/ehjci/jead030.
9
Nuclear Molecular Imaging of Disease Burden and Response to Treatment for Cardiac Amyloidosis.心脏淀粉样变性疾病负担及治疗反应的核分子成像
Biology (Basel). 2022 Sep 24;11(10):1395. doi: 10.3390/biology11101395.
10
Reverse cardiac remodelling and dysfunction in A97S transthyretin cardiac amyloidosis after tafamidis treatment.特立氟胺治疗后 A97S 转甲状腺素蛋白心脏淀粉样变的心脏逆重构和功能障碍。
ESC Heart Fail. 2022 Dec;9(6):4335-4339. doi: 10.1002/ehf2.14165. Epub 2022 Sep 20.